Globeflex Capital L P Makes New $1.15 Million Investment in Mesa Laboratories, Inc. $MLAB

Globeflex Capital L P purchased a new stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 11,581 shares of the medical instruments supplier’s stock, valued at approximately $1,153,000.

A number of other institutional investors also recently modified their holdings of the business. Boston Partners increased its position in Mesa Laboratories by 86.6% during the 4th quarter. Boston Partners now owns 213,376 shares of the medical instruments supplier’s stock worth $16,752,000 after purchasing an additional 99,019 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor bought a new position in Mesa Laboratories in the 2nd quarter valued at approximately $15,507,000. Royce & Associates LP grew its stake in shares of Mesa Laboratories by 3.2% during the fourth quarter. Royce & Associates LP now owns 153,352 shares of the medical instruments supplier’s stock worth $12,038,000 after buying an additional 4,794 shares during the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Mesa Laboratories by 19.0% during the fourth quarter. Kennedy Capital Management LLC now owns 144,606 shares of the medical instruments supplier’s stock worth $11,352,000 after buying an additional 23,060 shares in the last quarter. Finally, Diamond Hill Capital Management Inc. increased its holdings in shares of Mesa Laboratories by 15.1% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 141,973 shares of the medical instruments supplier’s stock worth $11,145,000 after buying an additional 18,592 shares in the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

Insider Activity at Mesa Laboratories

In related news, CFO John Sakys sold 2,827 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $89.50, for a total transaction of $253,016.50. Following the completion of the transaction, the chief financial officer directly owned 19,785 shares in the company, valued at $1,770,757.50. The trade was a 12.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brian David Archbold sold 2,516 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total transaction of $225,182.00. Following the completion of the transaction, the senior vice president directly owned 6,377 shares in the company, valued at $570,741.50. The trade was a 28.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 15,370 shares of company stock valued at $1,570,213 in the last quarter. 2.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Weiss Ratings upgraded shares of Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Wall Street Zen cut shares of Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, Wells Fargo & Company raised their price target on shares of Mesa Laboratories from $94.00 to $110.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $110.00.

Mesa Laboratories Price Performance

Shares of NASDAQ MLAB opened at $124.32 on Tuesday. The stock has a market cap of $696.19 million, a price-to-earnings ratio of 148.00 and a beta of 0.92. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.32 and a current ratio of 1.79. Mesa Laboratories, Inc. has a fifty-two week low of $58.83 and a fifty-two week high of $125.30. The firm’s 50-day simple moving average is $101.87 and its 200 day simple moving average is $97.61.

Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.The company had revenue of $60.14 million during the quarter.

Mesa Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Monday, August 31st. This represents a $0.64 annualized dividend and a yield of 0.5%. Mesa Laboratories’s payout ratio is currently 76.19%.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.